Montelukast Dorom (Montelukast)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1. This prevents leukotrienes D4, E4 and I4 from triggering bronchoconstriction, mucus production, and vascular leakage in the airways, thereby decreasing inflammation and easing breathing difficulties associated with asthma and allergic rhinitis.

The specific dose of Montelukast Dorom is determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and response to therapy. Healthcare professionals follow approved labeling and clinical guidelines to set an appropriate regimen for each individual.

Safety data for Montelukast in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when possible. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Montelukast Dorom, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic rhinitis, though it may be less potent than inhaled steroids for severe asthma.

Montelukast Dorom tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve potency and ensures product stability throughout its shelf life.

Montelukast Dorom is taken orally, usually as a whole tablet with or without food. The exact timing (morning or evening) and frequency are set by the prescriber, who tailors the regimen to the patient’s therapeutic needs and lifestyle.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like mood changes or suicidal thoughts, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Dorom is contraindicated in individuals with known hypersensitivity to Montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those who have experienced serious allergic reactions to other leukotriene‑modifying agents.